| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.2011.575359 |
| P698 | PubMed publication ID | 21466412 |
| P2093 | author name string | Young Sun Kang | |
| Dae Ryong Cha | |||
| Young Youl Hyun | |||
| Jin Joo Cha | |||
| P2860 | cites work | Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2. | Q54734811 |
| Chemokines control fat accumulation and leptin secretion by cultured human adipocytes | Q57076426 | ||
| Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells | Q58831541 | ||
| Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages | Q21296830 | ||
| Inflammation and insulin resistance | Q22241893 | ||
| Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle | Q22253922 | ||
| Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails | Q24310185 | ||
| Effects of diabetes and hypertension on macrophage infiltration and matrix expansion in the rat kidney | Q24810948 | ||
| High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR | Q27731247 | ||
| Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance | Q28131660 | ||
| Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE | Q28236539 | ||
| Recent developments in CCR2 antagonists | Q28244881 | ||
| Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant | Q28252699 | ||
| Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes | Q28575190 | ||
| Obesity induces a phenotypic switch in adipose tissue macrophage polarization | Q29547686 | ||
| MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity | Q29614283 | ||
| CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity | Q29617380 | ||
| Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters | Q29617381 | ||
| The many roles of chemokines and chemokine receptors in inflammation | Q29618880 | ||
| Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB | Q29619314 | ||
| IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance | Q29619774 | ||
| Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones | Q29622840 | ||
| CCR2 modulates inflammatory and metabolic effects of high-fat feeding | Q29622869 | ||
| GM-CSF action in the CNS decreases food intake and body weight | Q30476295 | ||
| Small molecule inhibitors of the CCR2b receptor. Part 1: Discovery and optimization of homopiperazine derivatives | Q31117152 | ||
| CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound | Q31436095 | ||
| Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells | Q33667974 | ||
| C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis | Q33750735 | ||
| Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity | Q33930230 | ||
| The metabolic syndrome and adipocytokines | Q33995630 | ||
| Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance | Q33997240 | ||
| Chemokines in renal diseases | Q34253917 | ||
| Role of chemokines in the pathogenesis of asthma | Q34572155 | ||
| Blockade of CCR2 ameliorates progressive fibrosis in kidney. | Q35102859 | ||
| Monocyte chemoattractant protein 1 in obesity and insulin resistance | Q35163496 | ||
| CSF-1 regulation of the wandering macrophage: complexity in action | Q35935793 | ||
| Chemokines in rheumatic diseases | Q36384814 | ||
| Obesity-induced inflammation: a metabolic dialogue in the language of inflammation | Q36944100 | ||
| Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes | Q36975445 | ||
| The role of GM-CSF in adipose tissue inflammation. | Q36977013 | ||
| Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes | Q37317440 | ||
| Monocyte chemoattractant protein-1 (MCP-1): an overview | Q37481208 | ||
| Chemokine receptor antagonists: Part 1. | Q37481238 | ||
| Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists | Q37500718 | ||
| Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications | Q37536067 | ||
| Innate immunity and adipose tissue biology | Q37740579 | ||
| Role of CC chemokine receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue. | Q38359435 | ||
| MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells | Q38500312 | ||
| Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. | Q40364641 | ||
| Chemokines, leukocyte trafficking, and inflammation | Q40502969 | ||
| Small molecule antagonists of the CCR2b receptor. Part 2: Discovery process and initial structure-activity relationships of diamine derivatives | Q40509831 | ||
| CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach | Q40638101 | ||
| Long-term treatment with propagermanium suppresses atherosclerosis in WHHL rabbits | Q40675011 | ||
| Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration. | Q40724596 | ||
| Expression of functional CCR and CXCR chemokine receptors in podocytes | Q40726391 | ||
| An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2. | Q40794333 | ||
| Renal glucose production and utilization: new aspects in humans | Q41550725 | ||
| CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice | Q42945868 | ||
| Newly identified adipose tissue macrophage populations in obesity with distinct chemokine and chemokine receptor expression. | Q43049709 | ||
| C-C chemokine receptor 2 inhibitor improves diet-induced development of insulin resistance and hepatic steatosis in mice | Q43152460 | ||
| An increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice | Q43415779 | ||
| Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists | Q43713819 | ||
| Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells | Q43931414 | ||
| Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. | Q44030294 | ||
| Propagermanium suppresses macrophage-mediated formation of coronary arteriosclerotic lesions in pigs in vivo | Q44327618 | ||
| Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy | Q46092513 | ||
| Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. | Q46345972 | ||
| Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series. | Q46723423 | ||
| Monocyte chemoattractant protein deficiency fails to restrain macrophage infiltration into adipose tissue [corrected]. | Q46759009 | ||
| Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice | Q46865455 | ||
| 4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties. | Q51805566 | ||
| Protection against concanavalin A-induced murine liver injury by the organic germanium compound, propagermanium. | Q52180932 | ||
| Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. | Q52566078 | ||
| Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. | Q53556065 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metabolic disease | Q2351083 |
| P304 | page(s) | 745-756 | |
| P577 | publication date | 2011-04-06 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments | |
| P478 | volume | 20 |
| Q35404963 | Aberrant accumulation of undifferentiated myeloid cells in the adipose tissue of CCR2-deficient mice delays improvements in insulin sensitivity. |
| Q42848637 | Adipose Tissue Dendritic Cells Are Independent Contributors to Obesity-Induced Inflammation and Insulin Resistance. |
| Q34444895 | Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease |
| Q47446039 | Association between monocyte chemoattractant protein-1 and blood pressure in smokers. |
| Q37692555 | Chemokine network during adipogenesis in 3T3-L1 cells: Differential response between growth and proinflammatory factor in preadipocytes vs. adipocytes |
| Q26752316 | Consumption of Substances of Abuse during Pregnancy Increases Consumption in Offspring: Possible Underlying Mechanisms |
| Q39550213 | Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5. |
| Q48345042 | Dual CCR2/5 Antagonist Attenuates Obesity-Induced Insulin Resistance by Regulating Macrophage Recruitment and M1/M2 Status. |
| Q36466014 | Effects of Toll-like receptor antagonist 4,5-dihydro-3-phenyl-5-isoxasole acetic acid on the progression of kidney disease in mice on a high-fat diet |
| Q37300443 | Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. |
| Q51120189 | Enhancement of macrophage inflammatory responses by CCL2 is correlated with increased miR-9 expression and downregulation of the ERK1/2 phosphatase Dusp6. |
| Q92152325 | Increase in IGF-1 Expression in the Injured Infraorbital Nerve and Possible Implications for Orofacial Neuropathic Pain |
| Q35691449 | Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway |
| Q37466096 | Innate immune activation in obesity |
| Q37432097 | International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors |
| Q38616998 | Intravenous immune-modifying nanoparticles as a therapy for spinal cord injury in mice |
| Q30423561 | Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury |
| Q38414881 | Pharmacokinetics of YJC-10592, a novel chemokine receptor 2 (CCR-2) antagonist, in rats |
| Q38083321 | Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012. |
| Q92860844 | Reappraising the role of inflammation in heart failure |
| Q39778136 | Targeting CCR2 Receptor To Treat Inflammation Diseases and Disorders |
| Q37436781 | The metabolic syndrome and neuropathy: therapeutic challenges and opportunities |
| Q28305924 | Therapeutic inflammatory monocyte modulation using immune-modifying microparticles |
| Q92490672 | Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672 |
Search more.